» Articles » PMID: 31396918

Osteoglycin and Bone-a Systematic Review

Overview
Publisher Current Science
Date 2019 Aug 10
PMID 31396918
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose Of Review: Bone turnover is a regulated process. Osteoglycin is suggested to have an important impact on bone function but may also affect cardiovascular and metabolic functions. This review investigates the action of osteoglycin in bone as well as its potential endocrine effects.

Recent Findings: Osteoglycin is expressed by several tissues including bone and muscle. Some studies suggest that osteoglycin increases osteoblast differentiation whereas others suggest that osteoglycin decreases osteoblast differentiation. Thus, findings on the influence of osteoglycin in bone are conflicting. A recent study found increased bone mass in osteoglycin deficient mice. Another study reported that osteoglycin is a marker of low bone mineral density and vertebral fractures in women with type 2 diabetes. Furthermore, clinical studies link osteoglycin to insulin resistance and cardiovascular disease. Osteoglycin may be a novel marker of a muscle, pancreatic, and bone axis. However, current evidence is limited and further research investigating osteoglycin in both a pre-clinical and a clinical setting is needed.

Citing Articles

Proteomic Analysis of Human Serum Proteins Adsorbed onto Collagen Barrier Membranes.

Shanbhag S, Al-Sharabi N, Fritz-Wallace K, Kristoffersen E, Bunaes D, Romandini M J Funct Biomater. 2024; 15(10).

PMID: 39452600 PMC: 11508515. DOI: 10.3390/jfb15100302.


Proteomic insights into extracellular vesicles in ALS for therapeutic potential of Ropinirole and biomarker discovery.

Kato C, Ueda K, Morimoto S, Takahashi S, Nakamura S, Ozawa F Inflamm Regen. 2024; 44(1):32.

PMID: 38997748 PMC: 11241965. DOI: 10.1186/s41232-024-00346-1.


Association between bone turnover markers, bone mineral density, and serum osteoglycine in middle-aged men with Type 2 Diabetes mellitus.

Mostafa S, Elebrashy I, Haddad H, Shaker O, Razek N, Fayed A Diabetol Metab Syndr. 2024; 16(1):155.

PMID: 38982537 PMC: 11232153. DOI: 10.1186/s13098-024-01388-8.


miRNA-seq analysis of high glucose induced osteoblasts provides insight into the mechanism underlying diabetic osteoporosis.

Zhang Y, Li M, Lou P, Zhang M, Shou D, Tong P Sci Rep. 2024; 14(1):13441.

PMID: 38862780 PMC: 11166950. DOI: 10.1038/s41598-024-64391-z.


Bone metabolism in diabetes: a clinician's guide to understanding the bone-glucose interplay.

Sheu A, White C, Center J Diabetologia. 2024; 67(8):1493-1506.

PMID: 38761257 PMC: 11343884. DOI: 10.1007/s00125-024-06172-x.


References
1.
Manolagas S, Almeida M . Gone with the Wnts: beta-catenin, T-cell factor, forkhead box O, and oxidative stress in age-dependent diseases of bone, lipid, and glucose metabolism. Mol Endocrinol. 2007; 21(11):2605-14. DOI: 10.1210/me.2007-0259. View

2.
Starup-Linde J, Vestergaard P . Biochemical bone turnover markers in diabetes mellitus - A systematic review. Bone. 2015; 82:69-78. DOI: 10.1016/j.bone.2015.02.019. View

3.
Westberg-Rasmussen S, Starup-Linde J, Hermansen K, Holst J, Hartmann B, Vestergaard P . Differential impact of glucose administered intravenously or orally on bone turnover markers in healthy male subjects. Bone. 2017; 97:261-266. DOI: 10.1016/j.bone.2017.01.027. View

4.
Boyle W, Simonet W, Lacey D . Osteoclast differentiation and activation. Nature. 2003; 423(6937):337-42. DOI: 10.1038/nature01658. View

5.
Delmas P . What do we know about biochemical bone markers?. Baillieres Clin Obstet Gynaecol. 1991; 5(4):817-30. DOI: 10.1016/s0950-3552(05)80289-5. View